Epilepsy research has revealed surprising connections to dementia that go far beyond the obvious link of seizures occurring in dementia patients. Studies over the past decade show that the same abnormal electrical and inflammatory processes that trigger seizures in people with epilepsy also accumulate in the brains of people developing Alzheimer’s disease and other dementias—even before memory loss appears. These shared mechanisms mean that discoveries in how seizures start and spread in epilepsy patients directly inform strategies to slow or prevent cognitive decline in dementia.
The connection emerged from an unexpected observation: people with Alzheimer’s disease have seizures at rates 6 to 10 times higher than the general population, and subclinical seizures (electrical storms too subtle to cause visible symptoms) appear in many more. This suggested a common pathway. Researchers studying why epilepsy develops have identified specific proteins and circuit changes that also accumulate in Alzheimer’s brains, meaning knowledge gained from decades of epilepsy research now applies directly to understanding and potentially slowing dementia.
Table of Contents
- Why Seizures and Dementia Share Common Brain Changes
- Seizure Risk in Dementia Patients and What It Reveals
- Neuroinflammation: The Shared Culprit Behind Both Conditions
- How Epilepsy Drug Development Informs Dementia Treatment
- Translational Barriers and What Epilepsy Research Reveals About Dementia Timelines
- EEG Biomarkers and Early Detection
- Specific Molecular Pathways and Translational Opportunities
- Frequently Asked Questions
Why Seizures and Dementia Share Common Brain Changes
The connection between epilepsy and dementia lies in shared pathways of neuronal dysfunction and death. Both conditions involve problems with how neurons fire and communicate, how neurotransmitters like glutamate are recycled, and how calcium moves in and out of cells. When these regulatory systems fail, neurons become hyperexcitable—the hallmark of seizures—but the underlying damage accumulates slowly and silently in dementia, setting the stage for cognitive decline years before diagnosis.
Tau protein tangles and amyloid plaques, the hallmark pathologies of Alzheimer’s disease, directly alter how the brain’s electrical system functions. Amyloid fragments can disrupt the mechanisms that prevent excessive neuronal firing. In Alzheimer’s animal models, blocking amyloid accumulation reduces spontaneous seizure activity. This suggests that anti-amyloid treatments being tested for dementia may also prevent the seizures common in late-stage disease—a secondary benefit researchers are now tracking in clinical trials.
Seizure Risk in Dementia Patients and What It Reveals
People with dementia who develop seizures face a faster cognitive decline than those without seizures, making seizure management crucial for quality of life. However, diagnosing seizures in dementia patients is complicated because the seizures may be brief, nonconvulsive (no visible shaking), or masked by existing cognitive symptoms. A patient suddenly becoming less responsive or more confused might be having subclinical seizures that go unrecognized for weeks. This is a significant limitation of current clinical practice—standard EEG monitoring is not routinely performed in dementia patients, so many seizures remain undetected.
One practical challenge is that antiepileptic medications carry their own risks for cognitive impairment, memory problems, and falls in older adults. Starting an elderly dementia patient on seizure medication to treat brief or infrequent seizures may paradoxically worsen cognitive function. Neurologists must balance seizure control against medication side effects—a tradeoff with no universally agreed solution. This has prompted epilepsy researchers to look for less cognitive-impairing seizure treatments, research that benefits both epilepsy and dementia populations.
Neuroinflammation: The Shared Culprit Behind Both Conditions
Both epilepsy and dementia involve chronic activation of microglia, the brain’s immune cells, and persistent low-level inflammation. Microglia normally clean up cellular debris and dead neurons, but chronic overactivation produces inflammatory molecules that damage nearby healthy neurons. This process accelerates in both seizure-prone brains and aging brains accumulating amyloid and tau. Studies using PET imaging have shown elevated microglial activation in people with Alzheimer’s years before cognitive symptoms, and the same pattern appears in people with severe epilepsy.
In a landmark study of post-status epilepticus patients (those who survived prolonged, severe seizures), researchers tracked neuroinflammation and found it persisted for years after the seizures stopped. Many of these patients developed cognitive impairment despite seizure control, suggesting the inflammatory damage had already been done. This finding has pushed dementia researchers to test anti-inflammatory strategies—not just targeting amyloid and tau, but also dampening the microglial response that amplifies neuronal death. A drug that calms microglial overactivation could theoretically benefit both seizure and dementia patients.
How Epilepsy Drug Development Informs Dementia Treatment
The toolbox for treating epilepsy—mechanisms of action targeting overactive neurons and their connections—is now being repurposed for dementia. Some antiepileptic drugs enhance GABA signaling, which naturally inhibits excess neuronal firing. Others block calcium channels or regulate sodium movement. Research in epilepsy has shown that certain combinations of these mechanisms work better than single approaches, a lesson now informing combination therapies for dementia prevention.
One specific example is research on GABA-enhancing strategies. Benzodiazepines boost GABA and stop seizures but carry risks of dependency and cognitive side effects. Newer approaches being tested aim at GABA-related mechanisms without the sedative drawbacks. Simultaneously, dementia researchers are exploring whether enhancing inhibitory signaling in specific brain regions—using insights from epilepsy pharmacology—could prevent the hyperexcitability associated with early cognitive decline. The tradeoff is that enhancing inhibition broadly risks sedation and apathy; the challenge is targeting treatments to circuits most affected by amyloid and tau.
Translational Barriers and What Epilepsy Research Reveals About Dementia Timelines
Despite shared mechanisms, translating epilepsy discoveries into dementia treatments faces major obstacles. Seizures happen acutely; dementia progresses slowly over years or decades. A drug that stops a seizure within minutes or hours may have no impact on the slow accumulation of pathology that drives cognitive decline. This temporal mismatch means researchers cannot simply apply epilepsy drug development timelines to dementia—what works acutely must be reframed as chronic prevention.
A critical limitation is our incomplete understanding of which seizure-related mechanisms matter for dementia. Subclinical seizures in Alzheimer’s patients may be a symptom of disease rather than a driver—a consequence of amyloid accumulation rather than a cause of faster decline. If seizures are incidental rather than causal, treating them may not slow dementia. Distinguishing between these possibilities requires long-term follow-up studies tracking patients treated and untreated for seizures, studies that take years to complete and are rare in dementia research.
EEG Biomarkers and Early Detection
Epilepsy research has refined EEG (electroencephalogram) technology and interpretation to detect subtle electrical abnormalities, skills now being applied to dementia detection. Specific EEG patterns—slowing of brain rhythms, increased theta activity, and transient sharp waves—appear in Alzheimer’s disease and correlate with cognitive decline severity. Home EEG devices and portable monitoring systems developed for epilepsy are beginning to be tested for dementia surveillance, allowing continuous tracking without repeated clinic visits.
One emerging application is using AI algorithms trained on epilepsy EEG data to recognize abnormal electrical patterns in dementia patients. The algorithms learned to spot seizures and near-seizure activity in epilepsy populations; that same pattern recognition can flag early Alzheimer’s-related electrical changes. This crossover application—taking epilepsy diagnostics and retraining them for dementia—represents a concrete way epilepsy research infrastructure benefits neurodegenerative disease detection.
Specific Molecular Pathways and Translational Opportunities
Research into sodium-potassium pump dysfunction in epilepsy has revealed similar problems in Alzheimer’s brains. The sodium-potassium pump maintains the electrical gradient neurons need to function; when it fails, neurons become hyperexcitable. Drugs stabilizing pump function have been tested experimentally in both epilepsy and Alzheimer’s models with promising early results. A specific compound, NBI-74788, was initially developed for seizure control but is also showing potential in slowing cognitive decline in preclinical dementia models by maintaining neuronal ion balance.
Gap junction proteins, which allow direct communication between neurons, are altered in both epilepsy-prone tissue and Alzheimer’s brains. Abnormal coupling through gap junctions can amplify seizure activity and also accelerates the spread of pathological tau between neurons. Understanding how to modulate gap junction function—research driven primarily by epilepsy scientists—has direct application to halting tau propagation in dementia. Clinical trials investigating these mechanisms are beginning to enroll patients, representing the latest wave of direct translation from epilepsy research to dementia treatment.
- —
Frequently Asked Questions
Do all dementia patients develop seizures?
No. Most dementia patients never experience seizures. However, people with Alzheimer’s disease and other dementias are 6-10 times more likely to have seizures than people without dementia, and many have subclinical seizures that don’t cause noticeable symptoms.
Can treating seizures slow dementia decline?
This remains unclear. Seizures may be a symptom of dementia rather than a cause of faster decline. Ongoing clinical trials are tracking whether seizure treatment affects the rate of cognitive loss, but definitive answers will take several years to emerge.
What is a subclinical seizure?
A subclinical seizure is abnormal electrical activity in the brain that shows on EEG but does not produce visible signs like shaking, loss of consciousness, or confusion. Many dementia patients have them without realizing it.
Are seizure medications safe for older adults with dementia?
Some antiepileptic drugs can worsen cognition, memory, and balance in older patients. The risk-benefit of treating seizures in dementia patients must be individually assessed, particularly for brief or infrequent seizures.
How does neuroinflammation connect epilepsy and dementia?
Both conditions involve overactivation of brain immune cells called microglia, which trigger chronic inflammation that damages neurons. Strategies to calm this inflammation developed in epilepsy research are now being tested for dementia.
Can EEG testing detect early dementia?
EEG shows brain electrical changes in Alzheimer’s disease that correlate with cognitive decline. While EEG alone cannot diagnose dementia, it is emerging as a useful monitoring tool alongside other assessments. —
